Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
ADL Bionatur Solutions. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
ADL Bionatur Solutions's
is considered below, and whether this is a fair price.
Price based on past earnings
ADL Bionatur Solutions's earnings available for a low price, and how does
this compare to other companies in the same industry?
ADL Bionatur Solutions's earnings are expected to grow significantly at over 20% yearly.
ADL Bionatur Solutions's revenue is expected to grow by 19.8% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
ADL Bionatur Solutions's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
ADL Bionatur Solutions
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
ADL Bionatur Solutions's finances.
The net worth of a company is the difference between its assets and liabilities.
ADL Bionatur Solutions is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
ADL Bionatur Solutions's long term commitments exceed its cash and other short term assets.
This treemap shows a more detailed breakdown of
ADL Bionatur Solutions's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
High level of physical assets or inventory.
Debt is not covered by short term assets, assets are 0.5x debt.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
Pilarde la Huerta
Ms. Pilar de la Huerta serves as Chief Executive Officer and Director of ADL Bionatur Solutions, S.A. She has been Member of Supervisory Board of Sygnis AG since July 7, 2017. Ms. de la Huerta served as the Co-Chief Executive Officer of Sygnis AG from March 31, 2013 to July 7, 2017, Chief Business Development Officer since March 1, 2017 and as its Member of Management Board until July 7, 2017. Ms. de la Huerta served as Chief Financial Officer of Sygnis AG from March 31, 2013 to March 1, 2017. Ms. de la Huerta served as the Chief Executive Officer of Genetrix S.L. and served as its Chairman. She served as the Chief Executive Officer of Sygnis Pharma AG since October 17, 2012 and served as its Member of Management Board. She joined Genetrix in 2010 from Viamed Salud where she was responsible for the R&D an New businesses area and was the Chief Executive Officer of Araclon Biotech, SL. Before of that, she served as Chief Executive Officer of Neuropharma and assumed different responsibilities within the Zeltia Group. With a massive experience in the biotechnology sector, she has assumed relevant responsibilities in biotech companies for the last 10 years. She has high value-added experience in formulating business structures and strategies, with direct experience in creating and managing companies in the biotech field. She has been a Member of Supervisory Board of Sygnis AG since July 7, 2017. Ms. de la Huerta served as a Director of Genetrix S.L. She served as a Director of Cellerix, S.A. She holds a Bachelor’s and Master Degree in Business and Administration by the UCM and has completed the IESE’s Advanced Management Program (AMP) and Program for Management Development (PMD) courses in the Navarra University.
Insufficient data for Pilar to compare compensation growth.
Insufficient data for Pilar to establish whether their remuneration is reasonable compared to companies of similar size in Spain.
ADL Bionatur Solutions, S.A. provides prescription drugs and non-prescription products for food production animals and pets. Its product pipeline comprises BNT006, a peptide-based nutritional supplement to increase livestock productivity; BNT007, a recombinant multivalent VLP antigen; BNT010, a recombinant DIVA antigen; BNT015, a recombinant VLP antigen for the treatment of viral infection; and BNT005 vaccines. ADL Bionatur Solutions, S.A. has a strategic alliance with Nutricion Center NC to launch NC Microbiota products for weight control for various age groups that act as abdominal fat burners, body fat burners, fat blockers, drains, antioxidant-drainers, and appetite inhibitors, as well as complemented with specific probiotic strains for balancing the gut microbiome. The company was formerly known as Bioorganic Research and Services S.A. ADL Bionatur Solutions, S.A. is headquartered in Jerez de la Frontera, Spain.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.